http://shionogi-prod.adobecqms.netshionogi.cahttp://www.shionogi.com/ca/en/products.htmlhttp://www.shionogi.com/ca/en/contact.htmlhttp://www.shionogi.com/ca/en/about.htmlhttp://www.shionogi.com/ca/en/about/people.htmlhttp://www.shionogi.com/ca/en/about/people/andy-zylak.htmlhttp://www.shionogi.com/ca/en/about/people/brad-alyward.htmlhttp://www.shionogi.com/ca/en/about/people/dung-pham.htmlhttp://www.shionogi.com/ca/en/about/people/louise-st-onge.htmlhttp://www.shionogi.com/ca/en/about/people/sophy-olafson.htmlhttp://www.shionogi.com/ca/en/about/people/steven-wainwright.htmlhttp://www.shionogi.com/ca/en/about/perspectives.htmlhttp://www.shionogi.com/ca/en/about/perspectives/q-a-andy-zylak.htmlhttp://www.shionogi.com/ca/en/about/brand-statement.htmlhttp://www.shionogi.com/ca/en/news.htmlhttp://www.shionogi.com/ca/en/news/press-releases.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2025.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2025/12.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2025/12/MTP-is-Now-Tanabe-Pharma-Canada.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2025/09.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2025/09/mtpca-announces-publication-long-term-function-and-survival-analysis-of-radicava-os-treated-patients-with-als.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2024.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2024/10.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2024/10/mtpca-to-discontinue-radicava-iv-edaravone.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/01.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/01/radicava-os-receives-positive-recommendation-from-cadth-treatment-als.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/02.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/02/MTPCA-announces-radicava-os-now-available-in-canada-for-treatment-als.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/03.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/03/MTPCA-receives-engagement-letter-pcpa-for-radicava-oral-suspension.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/04.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/04/Mitsubishi-Tanabe-Pharma-Canada-Announces-New-Leadership.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/06.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/06/MTPCA-support-new-hcp-directed-program-how-to-break-the-new-in-als-mnd.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/08.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/08/MTPCA-announces-oral-treatment-formulation-for-als-added-to-provincial-drug-plan-in-ontario.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/08/MTPCA-announces-oral-treatment-formulation-for-als-added-to-provincial-drug-plan-in-alberta.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/08/MTPCA-announces-collaboration-with-CNDR-on-First-Canadian-RWE-study-of-radicava-iv-survival-benefits-in-als.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/08/MTPCA-announces-oral-treatment-formulation-for-als-added-to-provincial-drug-plan-in-quebec.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/08/MTPCA-announces-oral-treatment-formulation-for-als-added-to-provincial-drug-plan-in-british-columbia.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/08/MTPCA-announces-oral-treatment-formulation-for-als-added-to-provincial-drug-plan-in-nova-scotia.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/09.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/09/MTPCA-announces-oral-treatment-formulation-for-als-added-to-provincial-drug-plan-in-saskatchewan.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/09/Canadian-Developed-AI-Technology-Aims-To-Support-Early-Detection-Of-ALS.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/11.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/11/MTPCA-announces-oral-treatment-formulation-for-als-added-to-provincial-drug-plans-in-PEI-Newfoundland-and-Labrador.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/11/MTPCA-Celebrates-Five-Years-in-Canada-Supporting-And-Committed-To-People-Living-With-ALS.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/12.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/12/MTPCA-announces-oral-treatment-formulation-for-als-eligible-veteran-affairs-canada-and-indigenous-services-canada.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/07.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2023/07/mtpca-concludes-letter-of-intent-with-pcpa-for-radicava-oral-suspension.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022/05.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022/05/Health-Canada-Accepts-SNDS-Filing-and-Grants-Priority-Review-Oral-Edaravone-Formulation-Treatment-ALS.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022/08.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022/08/MTPCA-Announces-Publication-of-Real-World-Data-for-Radicava-edaravone.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022/11.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022/11/MTPCA-announces-Canadian-authorization-radicava-oral-suspension-treatment-als.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022/12.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2022/12/radicava-os-receives-positive-recommendation-from-inesss-treatment-als.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2020.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2019.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2019/10.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2019/10/Update-on-Canadian-Product-Availability.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2019/11.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2019/11/Mitsubishi-Tanabe-Pharma-Canada-Announces-Availability-Of-RADICAVA-For-ALS.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2018.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2018/09.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2018/09/New-country-manager-brings-significant-business-leadership-and-healthcare-expertise-to-mitsubishi-tanabe-pharma-canada,.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2018/10.htmlhttp://www.shionogi.com/ca/en/news/press-releases/2018/10/Mitsubishi-Tanabe-Pharma-Canada-Announces-Canadian-Authorization-Of-RADICAVA-To-Treat-ALS.htmlhttp://www.shionogi.com/ca/en/worldwide.htmlhttp://www.shionogi.com/ca/en/investors.htmlhttp://www.shionogi.com/ca/en/privacy-policy.htmlhttp://www.shionogi.com/ca/en/terms-of-use.htmlhttp://www.shionogi.com/ca/en/careers.htmlhttp://www.shionogi.com/ca/en/innovation.htmlhttp://www.shionogi.com/ca/en/innovation/science.htmlhttp://www.shionogi.com/ca/en/innovation/science/clinical-trials-and-special-access.htmlhttp://www.shionogi.com/ca/en/innovation/science/pipeline.htmlhttp://www.shionogi.com/ca/en/innovation/science/clinical-development.htmlhttp://www.shionogi.com/ca/en/innovation/medical-information.htmlhttp://www.shionogi.com/ca/en/innovation/partners.htmlhttp://www.shionogi.com/ca/en/cookie-policy.htmlhttp://www.shionogi.com/ca/en/partner.html